Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines
Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived fr...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 January 2019
|
| In: |
Trends in molecular medicine
Year: 2019, Jahrgang: 25, Heft: 2, Pages: 149-163 |
| ISSN: | 1471-499X |
| DOI: | 10.1016/j.molmed.2018.12.006 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.molmed.2018.12.006 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1471491418302405 
|
| Verfasserangaben: | Guido Moll, James A. Ankrum, Julian Kamhieh-Milz, Karen Bieback, Olle Ringdén, Hans-Dieter Volk, Sven Geissler, and Petra Reinke |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1677850507 | ||
| 003 | DE-627 | ||
| 005 | 20230428021858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190927s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molmed.2018.12.006 |2 doi | |
| 035 | |a (DE-627)1677850507 | ||
| 035 | |a (DE-599)KXP1677850507 | ||
| 035 | |a (OCoLC)1341244512 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Moll, Guido |e VerfasserIn |0 (DE-588)1177937549 |0 (DE-627)1049057120 |0 (DE-576)517619563 |4 aut | |
| 245 | 1 | 0 | |a Intravascular mesenchymal stromal/stem cell therapy product diversification |b time for new clinical guidelines |c Guido Moll, James A. Ankrum, Julian Kamhieh-Milz, Karen Bieback, Olle Ringdén, Hans-Dieter Volk, Sven Geissler, and Petra Reinke |
| 264 | 1 | |c 30 January 2019 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.11.2019 | ||
| 520 | |a Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues. Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR). Suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies. | ||
| 650 | 4 | |a CD142 | |
| 650 | 4 | |a cellular therapy | |
| 650 | 4 | |a hemocompatibility | |
| 650 | 4 | |a mesenchymal stromal/stem cell | |
| 650 | 4 | |a safety and efficacy | |
| 650 | 4 | |a tissue factor | |
| 650 | 4 | |a tissue source | |
| 700 | 1 | |a Bieback, Karen |d 1972- |e VerfasserIn |0 (DE-588)124509991 |0 (DE-627)376254653 |0 (DE-576)294206604 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Trends in molecular medicine |d Amsterdam [u.a.] : Elsevier Science, 2001 |g 25(2019), 2, Seite 149-163 |h Online-Ressource |w (DE-627)391368036 |w (DE-600)2155736-6 |w (DE-576)252209338 |x 1471-499X |7 nnas |a Intravascular mesenchymal stromal/stem cell therapy product diversification time for new clinical guidelines |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:2 |g pages:149-163 |g extent:15 |a Intravascular mesenchymal stromal/stem cell therapy product diversification time for new clinical guidelines |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.molmed.2018.12.006 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1471491418302405 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190927 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 124509991 |a Bieback, Karen |m 124509991:Bieback, Karen |d 60000 |d 63500 |e 60000PB124509991 |e 63500PB124509991 |k 0/60000/ |k 1/60000/63500/ |p 4 | ||
| 999 | |a KXP-PPN1677850507 |e 3518375032 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1677850507","person":[{"family":"Moll","role":"aut","display":"Moll, Guido","given":"Guido"},{"given":"Karen","display":"Bieback, Karen","role":"aut","family":"Bieback"}],"note":["Gesehen am 26.11.2019"],"language":["eng"],"name":{"displayForm":["Guido Moll, James A. Ankrum, Julian Kamhieh-Milz, Karen Bieback, Olle Ringdén, Hans-Dieter Volk, Sven Geissler, and Petra Reinke"]},"relHost":[{"title":[{"title_sort":"Trends in molecular medicine","title":"Trends in molecular medicine"}],"id":{"zdb":["2155736-6"],"issn":["1471-499X"],"eki":["391368036"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"2001","dateIssuedDisp":"2001-","publisher":"Elsevier Science"}],"recId":"391368036","disp":"Intravascular mesenchymal stromal/stem cell therapy product diversification time for new clinical guidelinesTrends in molecular medicine","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"part":{"text":"25(2019), 2, Seite 149-163","issue":"2","pages":"149-163","extent":"15","volume":"25","year":"2019"},"pubHistory":["7.2001 -"],"note":["Gesehen am 21.11.23"]}],"origin":[{"dateIssuedDisp":"30 January 2019","dateIssuedKey":"2019"}],"title":[{"subtitle":"time for new clinical guidelines","title":"Intravascular mesenchymal stromal/stem cell therapy product diversification","title_sort":"Intravascular mesenchymal stromal/stem cell therapy product diversification"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1677850507"],"doi":["10.1016/j.molmed.2018.12.006"]},"physDesc":[{"extent":"15 S."}]} | ||
| SRT | |a MOLLGUIDOBINTRAVASCU3020 | ||